Facilitated By

San Antonio Medical Foundation

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate The Efficacy And Safety Of CSL112 In Subjects With Acute Coronary Syndrome

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Funded by
Research Start Date

The primary objective of this study is to evaluate the efficacy of CSLl 12 on reducing the risk of major adverse cardiovascular event(s) (MACE) (Cardiovascular (CV) death, myocardial infarction (MI), or stroke) from the time of randomization through ninety (90) days in subjects with acute coronary syndrome (ACS) (diagnosed with ST-segment elevation myocardial infarction (STEM!) or Non-ST-segment elevation myocardial infarction (NSTEMI)).

Collaborative Project
Clinical Care
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.